Suppr超能文献

异常凝血酶原和甲胎蛋白在乙型肝炎病毒相关性肝细胞癌中的诊断价值

Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.

作者信息

Seo Seung In, Kim Hyoung Su, Kim Won Jin, Shin Woon Geon, Kim Doo Jin, Kim Kyung Ho, Jang Myoung Kuk, Lee Jin Heon, Kim Joo Seop, Kim Hak Yang, Kim Dong Joon, Lee Myung Seok, Park Choong Kee

机构信息

Seung In Seo, Hyoung Su Kim, Won Jin Kim, Woon Geon Shin, Kyung Ho Kim, Myoung Kuk Jang, Jin Heon Lee, Hak Yang Kim, Dong Joon Kim, Myung Seok Lee, Choong Kee Park, Department of Internal Medicine, Hallym University Medical Center, Seoul 134-701, South Korea.

出版信息

World J Gastroenterol. 2015 Apr 7;21(13):3928-35. doi: 10.3748/wjg.v21.i13.3928.

Abstract

AIM

To determine the cutoff values and to compare the diagnostic role of alpha-fetoprotein (AFP) and prothrombin induced by vitamin K absence-II (PIVKA-II) in chronic hepatitis B (CHB).

METHODS

A total of 1255 patients with CHB, including 157 patients with hepatocellular carcinoma (HCC), 879 with non-cirrhotic CHB and 219 with cirrhosis without HCC, were retrospectively enrolled. The areas under the receiver operating characteristic (AUROC) curves of PIVKA-II, AFP and their combination were calculated and compared.

RESULTS

The optimal cutoff values for PIVKA-II and AFP were 40 mAU/mL and 10 ng/mL, respectively, for the differentiation of HCC from nonmalignant CHB. The sensitivity and specificity were 73.9% and 89.7%, respectively, for PIVKA-II and 67.5% and 90.3% for AFP, respectively. The AUROC curves of both PIVKA-II and AFP were not significantly different (0.854 vs 0.853, P = 0.965) for the differentiation of HCC from nonmalignant CHB, whereas the AUROC of PIVKA-II was significantly better than that of AFP in patients with cirrhosis (0.870 vs 0.812, P = 0.042). When PIVKA-II and AFP were combined, the diagnostic power improved significantly compared to either AFP or PIVKA-II alone for the differentiation of HCC from nonmalignant CHB (P < 0.05), especially when cirrhosis was present (P < 0.05).

CONCLUSION

Serum PIVKA-II might be a better tumor marker than AFP, and its combination with AFP may enhance the early detection of HCC in patients with CHB.

摘要

目的

确定临界值,并比较甲胎蛋白(AFP)和维生素K缺乏诱导蛋白-II(PIVKA-II)在慢性乙型肝炎(CHB)中的诊断作用。

方法

回顾性纳入1255例CHB患者,其中包括157例肝细胞癌(HCC)患者、879例非肝硬化CHB患者和219例无HCC的肝硬化患者。计算并比较PIVKA-II、AFP及其联合检测的受试者工作特征(AUROC)曲线下面积。

结果

对于HCC与非恶性CHB的鉴别,PIVKA-II和AFP的最佳临界值分别为40 mAU/mL和10 ng/mL。PIVKA-II的敏感性和特异性分别为73.9%和89.7%,AFP的敏感性和特异性分别为67.5%和90.3%。对于HCC与非恶性CHB的鉴别,PIVKA-II和AFP的AUROC曲线无显著差异(0.854对0.853,P = 0.965),而在肝硬化患者中,PIVKA-II的AUROC显著优于AFP(0.870对0.812,P = 0.042)。当PIVKA-II和AFP联合检测时,与单独使用AFP或PIVKA-II相比,对于HCC与非恶性CHB的鉴别,诊断效能显著提高(P < 0.05),尤其是在存在肝硬化的情况下(P < 0.05)。

结论

血清PIVKA-II可能是比AFP更好的肿瘤标志物,其与AFP联合使用可能提高CHB患者中HCC的早期检测率。

相似文献

1
Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.
World J Gastroenterol. 2015 Apr 7;21(13):3928-35. doi: 10.3748/wjg.v21.i13.3928.
2
Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
Scand J Gastroenterol. 2016 Mar;51(3):344-53. doi: 10.3109/00365521.2015.1082190. Epub 2015 Sep 4.
3
Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
Panminerva Med. 2017 Dec;59(4):283-289. doi: 10.23736/S0031-0808.17.03353-5. Epub 2017 Jun 23.
7
Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study.
Eur J Gastroenterol Hepatol. 2016 May;28(5):599-605. doi: 10.1097/MEG.0000000000000569.
8
Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
Scand J Gastroenterol. 2016 Oct;51(10):1257-62. doi: 10.1080/00365521.2016.1183705. Epub 2016 May 26.

引用本文的文献

1
Application of biological big data and radiomics in hepatocellular carcinoma.
ILIVER. 2023 Feb 4;2(1):41-49. doi: 10.1016/j.iliver.2023.01.003. eCollection 2023 Mar.
2
Predictive Factors and Nomogram (MAP-BNP) for Post Stereotactic Body Radiotherapy Survival in Advanced Hepatocellular Carcinoma Patients.
J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102555. doi: 10.1016/j.jceh.2025.102555. Epub 2025 Mar 28.
3
Strategies for discovering novel hepatocellular carcinoma biomarkers.
World J Hepatol. 2025 Feb 27;17(2):101201. doi: 10.4254/wjh.v17.i2.101201.
6
Novel biomarkers for monitoring and management of hepatocellular carcinoma.
Cancer Cell Int. 2024 Dec 24;24(1):428. doi: 10.1186/s12935-024-03600-1.
9
Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma.
Mol Cancer. 2024 Sep 6;23(1):189. doi: 10.1186/s12943-024-02101-z.
10
Redefining HCC Surveillance in India: A Call for Innovative and Inclusive Strategies.
J Clin Exp Hepatol. 2024 Nov-Dec;14(6):101474. doi: 10.1016/j.jceh.2024.101474. Epub 2024 Jun 25.

本文引用的文献

1
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.
J Hepatol. 2012 Apr;56(4):908-43. doi: 10.1016/j.jhep.2011.12.001.
2
Management of hepatocellular carcinoma: an update.
Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.
3
Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin.
Liver Int. 2011 Jan;31(1):22-35. doi: 10.1111/j.1478-3231.2010.02348.x. Epub 2010 Sep 27.
5
Serum markers of hepatocellular carcinoma.
Dig Dis Sci. 2010 Oct;55(10):2744-55. doi: 10.1007/s10620-010-1184-7. Epub 2010 Mar 26.
7
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.
Gastroenterology. 2009 Jul;137(1):110-8. doi: 10.1053/j.gastro.2009.04.005. Epub 2009 Apr 9.
8
Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
J Gastroenterol Hepatol. 2008 Oct;23(10):1541-8. doi: 10.1111/j.1440-1746.2008.05395.x. Epub 2008 Apr 19.
9
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome.
Am J Med. 2008 Feb;121(2):119-26. doi: 10.1016/j.amjmed.2007.09.020.
10
Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.
Am J Gastroenterol. 2006 Sep;101(9):2038-43. doi: 10.1111/j.1572-0241.2006.00681.x. Epub 2006 Jul 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验